Menu Close

Trending

Huge inequalities found in access to myeloma clinical trials in Europe, says MPE
6th Annual 3D Cell Culture Conference
SMC gives Bayer’s CKD therapy Kerendia the green light in Scotland
Can VR technology make physical therapy fun? – the pharmaphorum podcast
Steps to building a more patient-centric industry

PCSK9 inhibitors

AstraZeneca plant. AstraZeneca has been working on a vaccine for the Coronavirus, COVID and COVID-19.

News/ News/ R&D

AZ and Ionis’ PCSK9 cholesterol drug will not move to phase 3

, , , , , , , , , , 0 Comment

AstraZeneca has taken the decision not to move a PCSK9-targeting antisense drug licensed from Ionis into a phase

X
AZ and Ionis’ PCSK9 cholesterol drug will not move to phase 3
https://pharmaphorum.com/news/az-and-ionis-pcsk9-cholesterol-drug-will-not-move-to-phase-3/
AstraZeneca (AZ)

News/ News/ R&D/ Top stories

AZ buys oral PCSK9 cholesterol drug from Dogma Therapeutics

, , , , , 0 Comment

AstraZeneca has bought rights to an orally-active drug that inhibits PCSK9, offering a patient-friendly alternative to current cholesterol-lowering

X
AZ buys oral PCSK9 cholesterol drug from Dogma Therapeutics
https://pharmaphorum.com/news/az-buys-oral-pcsk9-cholesterol-drug-from-dogma-therapeutics/
Stethescope heart

News/ News/ R&D

TMC’s inclisiran impresses at ESC, but will it surpass PCSK9 rivals?

, , , , , , , , , , , 0 Comment

Cardiologists only had to wait a few days after The Medicines Company teased top-line results with its cholesterol-lowering

X
TMC’s inclisiran impresses at ESC, but will it surpass PCSK9 rivals?
https://pharmaphorum.com/news/tmcs-inclisiran-impresses-at-esc-but-will-it-surpass-pcsk9-rivals/

Login

CONTINUE TO SITE >
X
Close in 10 seconds